These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 27126650)

  • 21. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis.
    Hum J; Shatzel JJ; Jou JH; Deloughery TG
    Eur J Haematol; 2017 Apr; 98(4):393-397. PubMed ID: 28009449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there a role for low-dose DOACs as prophylaxis?
    Cohen AT; Hunt BJ
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):187-193. PubMed ID: 31808883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral anticoagulant therapy. Fundamentals, clinical practice and recommendations.
    Lemos Silva R; Carvalho de Sousa J; Calisto C; Braz Nogueira JM; Ravara L
    Rev Port Cardiol; 2007; 26(7-8):769-88. PubMed ID: 17939586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?
    Margelidon-Cozzolino V; Delavenne X; Catella-Chatron J; De Magalhaes E; Bezzeghoud S; Humbert M; Montani D; Bertoletti L
    Blood Rev; 2019 Sep; 37():100579. PubMed ID: 31113643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants and consequences of differences in quality of anticoagulation therapy with vitamin K antagonists.
    Tichelaar V; Meijer K
    Thromb Res; 2015 Aug; 136(2):183-4. PubMed ID: 26024823
    [No Abstract]   [Full Text] [Related]  

  • 26. Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs).
    Di Minno A; Spadarella G; Tufano A; Prisco D; Di Minno G
    Thromb Res; 2014 May; 133(5):699-704. PubMed ID: 24525314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age-dependency of prescribing patterns of oral anticoagulant drugs in Austria during 2011-2014.
    Schuh T; Reichardt B; Finsterer J; Stöllberger C
    J Thromb Thrombolysis; 2016 Oct; 42(3):447-51. PubMed ID: 27221106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists- insights from the switching study.
    Bartoli-Abdou JK; Patel JP; Crawshaw J; Vadher B; Brown A; Roberts LN; Patel RK; Arya R; Auyeung V
    Thromb Res; 2018 Feb; 162():62-68. PubMed ID: 29306122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orally active direct thrombin inhibitors.
    Weitz J
    Semin Vasc Med; 2003 May; 3(2):131-8. PubMed ID: 15199476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ximelagatran.
    Choudhury A; Goyal D; Lip GY
    Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants.
    Prandoni P; Ageno W; Mumoli N; Zanatta N; Imberti D; Visonà A; Ciammaichella M; Simioni L; Cappelli R; Bucherini E; Di Nisio M; Avruscio G; Camporese G; Parisi R; Cuppini S; Turatti G; Noventa F; Sarolo L
    Thromb Res; 2017 May; 153():97-100. PubMed ID: 28364690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
    Marcy TR; Truong T; Rai A
    Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Will warfarin ever be replaced?
    Ruff CT; Braunwald E
    J Cardiovasc Pharmacol Ther; 2010 Sep; 15(3):210-9. PubMed ID: 20484119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis, prognosis and therapeutic management of acute pulmonary embolism.
    Tapson VF
    Hosp Pract (1995); 2016 Aug; 44(3):164-72. PubMed ID: 27450108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Direct Oral Anticoagulants in Patients with Splanchnic Vein Thrombosis: A Systematic Reviews and Meta-Analysis.
    Wan Y; Guo L; Xiong M
    Clin Appl Thromb Hemost; 2024; 30():10760296241274750. PubMed ID: 39135448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin K antagonists in anticoagulant therapy of patients with cancer.
    Pasierski T
    Pol Arch Med Wewn; 2012; 122(1-2):60-4. PubMed ID: 22353708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracranial complications after minor head injury (MHI) in patients taking vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs).
    Riccardi A; Spinola B; Minuto P; Ghinatti M; Guiddo G; Malerba M; Lerza R
    Am J Emerg Med; 2017 Sep; 35(9):1317-1319. PubMed ID: 28400068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [When to replace the vitamin K antagonists by new anticoagulants?].
    Fournet M; Daubert JC
    Rev Prat; 2013 Sep; 63(7):970-5. PubMed ID: 24167900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.